Critical Contrast: Entera Bio (NASDAQ:ENTX) and Kiromic BioPharma (NASDAQ:KRBP)

Entera Bio (NASDAQ:ENTX) and Kiromic BioPharma (NASDAQ:KRBP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

Analyst Recommendations

This is a summary of recent ratings for Entera Bio and Kiromic BioPharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entera Bio	0	0	1	0	3.00
Kiromic BioPharma	0	0	0	0	N/A

Entera Bio currently has a consensus price target of $10.00, indicating a potential upside of 426.32%. Given Entera Bio’s higher probable upside, equities research analysts plainly believe Entera Bio is more favorable than Kiromic BioPharma.

Institutional and Insider Ownership

14.1% of Entera Bio shares are held by institutional investors. Comparatively, 10.9% of Kiromic BioPharma shares are held by institutional investors. 10.9% of Entera Bio shares are held by company insiders. Comparatively, 20.6% of Kiromic BioPharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Entera Bio and Kiromic BioPharma’s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entera Bio	$130,000.00	523.01	-$8.89 million	($0.28)	-6.79
Kiromic BioPharma	N/A	N/A	-$20.95 million	($9.90)	-0.18

Entera Bio has higher revenue and earnings than Kiromic BioPharma. Entera Bio is trading at a lower price-to-earnings ratio than Kiromic BioPharma, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Entera Bio has a beta of 1.6, meaning that its stock price is 60% more volatile than the S&P 500. Comparatively, Kiromic BioPharma has a beta of 1.96, meaning that its stock price is 96% more volatile than the S&P 500.

Profitability

This table compares Entera Bio and Kiromic BioPharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Entera Bio	N/A	-103.40%	-85.00%
Kiromic BioPharma	N/A	N/A	-133.33%

Summary

Entera Bio beats Kiromic BioPharma on 7 of the 11 factors compared between the two stocks.

About Entera Bio

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

About Kiromic BioPharma

Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has a license agreement with Longwood University; and a research and development collaboration agreement with Molipharma, S.R.L. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.